Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...

Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...

Gilead ​Sciences said ‌on ​Monday ​it would ⁠buy ​privately ​held biotech firm ​Ouro ​Medicines in ‌a ⁠deal worth ​up ​to ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

Despite world-class AI-biotech research, a Nobel Prize-winning protein design lab and proximity to global AI expertise, Washington's life sciences sector is still learning to tell its story.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...